Japan-based Kaneka Corporation has signed a contract with Japan-based FUJIFILM Corporation to provide drug substances for anti-influenza drug, Avigan Tablet (generic name: favipiravir), for the treatment of novel coronavirus disease (COVID-19), it was reported on Thursday.
The Japanese government has decided to increase its stockpiles of Avigan Tablet, which is likely to be effective against COVID-19.
FUJIFILM Corporation has expanded its production system and started increasing its production of Avigan Tablets. The company said that it has already started supplying PCR reagents used for COVID-19 tests via its group company Kaneka Eurogentec (Headquarters: Belgium). In addition, it is enhancing its contracted manufacturing efforts for a COVID-19 vaccine, using technologies such as high-quality mRNA and plasmid DNA and is handling an onrush of inquiries.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US